U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927648) titled 'CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA' on April 14.
Brief Summary: To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.
Study Start Date: Dec. 31, 2025
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Digest....